Literature DB >> 12581140

Scleromyxedema revisited.

John J Pomann1, Earl J Rudner.   

Abstract

Scleromyxedema is a rare disease characterized by papular mucinous deposits, dermal fibroblast proliferation, and a monoclonal paraproteinemia. Its chronic course tends to be complicated by gastrointestinal, muscular, pulmonary, and neurologic disorders. We review the literature to identify the common systemic manifestations and suggest a clinical approach to this disorder. This should include: identification of the characteristic lesions, a skin biopsy, and serum protein electrophoresis. A thyroid evaluation may help differentiate this condition from others. An early neurologic, gastrointestinal, and cardiovascular evaluation should be considered.

Entities:  

Mesh:

Year:  2003        PMID: 12581140     DOI: 10.1046/j.1365-4362.2003.01565.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  17 in total

1.  Monoclonal gammopathy of undetermined significance: significant beyond hematology.

Authors:  Steven Vanderschueren; Marieke Mylle; Daan Dierickx; Michel Delforge; Peter Verhamme; Kathelijne Peerlinck; Wouter Meersseman; Daniël C Knockaert
Journal:  Mayo Clin Proc       Date:  2009-09       Impact factor: 7.616

2.  Scleroderma Mimickers.

Authors:  Nadia D Morgan; Laura K Hummers
Journal:  Curr Treatm Opt Rheumatol       Date:  2016-02-05

3.  [Scleromyxedema. A chronic progressive systemic disease].

Authors:  A Kreuter; M Stücker; A G A Kolios; P Altmeyer; K Möllenhoff
Journal:  Z Rheumatol       Date:  2012-08       Impact factor: 1.372

Review 4.  [Scleromyxedema].

Authors:  M Neufeld; C Sunderkötter; R K C Moritz
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

5.  Dermato-neuro syndrome in a case of scleromyxedema.

Authors:  Yusuf Savran; Sevgi Akarsu
Journal:  Eur J Rheumatol       Date:  2015-04-22

Review 6.  Scleroderma mimics.

Authors:  Jennifer Nashel; Virginia Steen
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

7.  Scleromyxedema: An Atypical Case.

Authors:  Emy Thomas; Anisha George; Divya Deodhar; Mary John
Journal:  Indian J Dermatol       Date:  2015 May-Jun       Impact factor: 1.494

8.  Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy.

Authors:  Julie Delyon; Maud Bézier; Michel Rybojad; Josette Brière; Pierre Validire; Martine Bagot; Anne Janin; Maxime Battistella
Journal:  Virchows Arch       Date:  2013-05-17       Impact factor: 4.064

9.  Systemic and cell type-specific gene expression patterns in scleroderma skin.

Authors:  Michael L Whitfield; Deborah R Finlay; John Isaac Murray; Olga G Troyanskaya; Jen-Tsan Chi; Alexander Pergamenschikov; Timothy H McCalmont; Patrick O Brown; David Botstein; M Kari Connolly
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-06       Impact factor: 11.205

Review 10.  Scleroderma-like fibrosing disorders.

Authors:  Francesco Boin; Laura K Hummers
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.